Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease
Inflammatory Bowel Diseases2011Vol. 18(7), pp. 1199–1206
Citations Over TimeTop 10% of 2011 papers
Benjamin Pariente, Guillaume Pineton de Chambrun, Roman Krzysiek, Marine Desroches, Gauthier Louis, Chiara De Cassan, Clotilde Baudry, Jean‐Marc Gornet, Pierre Desreumaux, Dominique Émilie, Jean–Frédéric Colombel, Matthieu Allez
Abstract
In patients with IBD who lose response to infliximab, clinical improvement may occur upon intensification of infliximab therapy, irrespective of infliximab serum concentration or presence of ATI.
Related Papers
- → Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis(2008)377 cited
- → Effectiveness of infliximab after adalimumab failure in Crohn's disease.(2012)32 cited
- Effectiveness of infliximab after adalimumab failure in Crohn＇s disease(2012)
- → Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease(2013)17 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited